Goldman Sachs Removed Mylan (MYL) from its Conviction Buy List
More News related to MYL
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
- Mylan Labs (MYL) Tops Q3 EPS by 5c, Guides Higher
- Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
More News related to Analyst Comments
- Goldman Sachs Added Cytec Industries (CYT) to their Conviction Sell List
- FBR Capital Recommends An IPO or Spin Off at Chesapeake Energy (CHK)
- Canaccord Adams Maintains a 'Buy' on Silver Wheaton (SLW); Raises Price Target
- Citi Boosts Target on McDonald's (MCD) to $64, Maintains Hold
- Canaccord Adams Reiterates a 'Buy' on Veeco Instruments (VECO); Raises PT & Estimates
Goldman Sachs removed Mylan, Inc. (NYSE: MYL) from its Conviction Buy List. The firm is maintaining a Buy rating on the stock.
Mylan Inc. and its subsidiaries engage in the development, manufacture, marketing, licensing, and distribution of generic, brand, and branded generic pharmaceutical products and active pharmaceutical ingredients.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Analyst CommentsStocks Mentioned
-0.34Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
